CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 31 enrolled
Drug / intervention
Mifepristone +1 moredrug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓HAM-D score of 20 or above (indicating moderate-to-severe depression)
  • ✓Age 18–75 years
  • ✓At least 2 failed adequate trials of antidepressant medication
  • ✓If on psychotropic medications, must be stable for ≥3 weeks prior to study entry
Key exclusion· 6
  • ✕History of schizophrenia or other psychotic disorders
  • ✕Transcranial magnetic stimulation or ECT within 3 months prior to study start
  • ✕Any history of vagus nerve stimulation treatment
  • ✕Unstable or untreated cardiovascular disease, hypertension, or endocrine disorder

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00186056
NCT00186056N/ACompleted
CompareCT.gov

Mifepristone in Refractory Depression

Stanford University·interventional·Posted Sep 16, 2005·Updated Apr 5, 2017

In Brief

A clinical study evaluating Mifepristone and Placebo Oral Tablet for Depression. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The purpose of the study is to examine the effectiveness of mifepristone treatment in patients with refractory depression. Refractory depression is defined as clinical depression that is unimproved after treatment with at least 2 different antidepressants of adequate dose and time trial. Mifepristone will augment current medications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartJan 1, 2003
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.8 years ago

Interventions

Mifepristonedrug

Glucocorticoid antagonist

Placebo Oral Tabletdrug

Inactive placebo tab